BEAM trial (antenatal magnesium sulfate and cerebral palsy)
A US trial that tested whether magnesium sulfate given to women at imminent risk of delivering between 24 and 31 weeks would lower the risk of death or moderate or severe cerebral palsy in their children. It did not lower the combined risk; cerebral palsy alone was less common with magnesium sulfate.
- Study
- In this atlas
Overview
- Design
- Multicentre, placebo-controlled, double-blind randomised trial of magnesium sulfate (6-g intravenous bolus then 2 g per hour) against matching placebo, given to women at imminent risk of delivery between 24 and 31 weeks of gestation. Registry: allocation randomised, masking triple, primary purpose prevention.
- Phase
- Phase 3
- Enrolled
- 2,136 participants (registry; ClinicalTrials.gov gives no unit)
- 2,241 women
- Sponsor
- Not recorded
- Funder
- Not recorded
- Registry
- Not reported
- Started
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Care setting
- Not reported
- Registry status
- “COMPLETED”
Technical summary
Registry NCT00014989 (phase 3, randomised, masking triple, status COMPLETED; the lead sponsor on the registry is The George Washington University Biostatistics Center) and the 2008 paper, whose collective author is the Maternal-Fetal Medicine Units Network (PubMed abstract only). The registry enrolment is 2136 (actual); the paper reports 2241 women randomised. The two counts are not reconciled here.
Arms
-
Magnesium sulfate
Intervention Magnesium sulfate before very preterm birth to protect the baby's brain
Intravenous 6-g bolus followed by a constant infusion of 2 g per hour (abstract).
-
Placebo
Intervention
Matching placebo (abstract).
Findings
No findings are published for this study.
Record details
- Record id
maternal:beam-trial- Content hash
0c1d6d74e250f856f1ab89bd3c66d0c67c83a313d83a4ecf4523269a3bc8be58